Contrasting toxicity data from CD19-directed CAR T cell trials with maturing data from several trials using CAR T cells in multiple myeloma may inform to what degrees toxicity profiles differ with the change of the target antigen—information that may help anticipate toxicity profiles with CAR-modified IECs in AML. Here, CD19 is linked to plasma cell myeloma.